Lipocine Inc.

Lipocine Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral delivery solutions for poorly bioavailable drugs. The company's primary focus is on pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. Its lead product candidate, TLANDO, is an oral testosterone replacement therapy. Lipocine's pipeline includes oral prodrugs of testosterone for various indications, such as non-alcoholic steatohepatitis, hypogonadism, decompensated cirrhosis, postpartum depression, and preterm birth prevention. The company generates revenue through the development and potential commercialization of these innovative oral drug delivery solutions for a range of medical conditions.

Products

• TLANDO - oral testosterone replacement therapy

• Pipeline candidates for various indications